Author
Listed:
- Ana Babic
(Dana-Farber Cancer Institute)
- Michael H. Rosenthal
(Brigham and Women’s Hospital and Harvard Medical School)
- Tilak K. Sundaresan
(Kaiser Permanente San Francisco)
- Natalia Khalaf
(Baylor College of Medicine)
- Valerie Lee
(Kaiser Permanente Northern California)
- Lauren K. Brais
(Dana-Farber Cancer Institute)
- Maureen Loftus
(Dana-Farber Cancer Institute)
- Leah Caplan
(Dana-Farber Cancer Institute)
- Sarah Denning
(Dana-Farber Cancer Institute)
- Anamol Gurung
(Dana-Farber Cancer Institute)
- Joanna Harrod
(Dana-Farber Cancer Institute)
- Khoschy Schawkat
(Brigham and Women’s Hospital and Harvard Medical School)
- Chen Yuan
(Dana-Farber Cancer Institute)
- Qiao-Li Wang
(Dana-Farber Cancer Institute
Karolinska Institutet)
- Alice A. Lee
(Brigham and Women’s Hospital and Harvard Medical School)
- Leah H. Biller
(Dana-Farber Cancer Institute
Brigham and Women’s Hospital and Harvard Medical School)
- Matthew B. Yurgelun
(Dana-Farber Cancer Institute
Brigham and Women’s Hospital and Harvard Medical School)
- Kimmie Ng
(Dana-Farber Cancer Institute
Brigham and Women’s Hospital and Harvard Medical School)
- Jonathan A. Nowak
(Brigham and Women’s Hospital and Harvard Medical School)
- Andrew J. Aguirre
(Dana-Farber Cancer Institute
Brigham and Women’s Hospital and Harvard Medical School)
- Sangeeta N. Bhatia
(Brigham and Women’s Hospital and Harvard Medical School
Massachusetts Institute of Technology
Massachusetts Institute of Technology
Massachusetts Institute of Technology)
- Matthew G. Heiden
(Dana-Farber Cancer Institute
Massachusetts Institute of Technology
Broad Institute of Massachusetts Institute of Technology and Harvard
Massachusetts Institute of Technology)
- Stephen K. Eeden
(Kaiser Permanente Northern California)
- Bette J. Caan
(Kaiser Permanente Northern California)
- Brian M. Wolpin
(Dana-Farber Cancer Institute
Brigham and Women’s Hospital and Harvard Medical School)
Abstract
Patients with pancreatic cancer commonly develop weight loss and muscle wasting. Whether adipose tissue and skeletal muscle losses begin before diagnosis and the potential utility of such losses for earlier cancer detection are not well understood. We quantify skeletal muscle and adipose tissue areas from computed tomography (CT) imaging obtained 2 months to 5 years before cancer diagnosis in 714 pancreatic cancer cases and 1748 matched controls. Adipose tissue loss is identified up to 6 months, and skeletal muscle wasting is identified up to 18 months before the clinical diagnosis of pancreatic cancer and is not present in the matched control population. Tissue losses are of similar magnitude in cases diagnosed with localized compared with metastatic disease and are not correlated with at-diagnosis circulating levels of CA19-9. Skeletal muscle wasting occurs in the 1–2 years before pancreatic cancer diagnosis and may signal an upcoming diagnosis of pancreatic cancer.
Suggested Citation
Ana Babic & Michael H. Rosenthal & Tilak K. Sundaresan & Natalia Khalaf & Valerie Lee & Lauren K. Brais & Maureen Loftus & Leah Caplan & Sarah Denning & Anamol Gurung & Joanna Harrod & Khoschy Schawka, 2023.
"Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer,"
Nature Communications, Nature, vol. 14(1), pages 1-9, December.
Handle:
RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-40024-3
DOI: 10.1038/s41467-023-40024-3
Download full text from publisher
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
- Ali Vaziri-Gohar & Jonathan J. Hue & Ata Abbas & Hallie J. Graor & Omid Hajihassani & Mehrdad Zarei & George Titomihelakis & John Feczko & Moeez Rathore & Sylwia Chelstowska & Alexander W. Loftus & Ru, 2023.
"Increased glucose availability sensitizes pancreatic cancer to chemotherapy,"
Nature Communications, Nature, vol. 14(1), pages 1-13, December.
- Yin Zhang & Qiao-Li Wang & Chen Yuan & Alice A. Lee & Ana Babic & Kimmie Ng & Kimberly Perez & Jonathan A. Nowak & Jesper Lagergren & Meir J. Stampfer & Edward L. Giovannucci & Chris Sander & Michael , 2023.
"Pancreatic cancer is associated with medication changes prior to clinical diagnosis,"
Nature Communications, Nature, vol. 14(1), pages 1-10, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-40024-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.